Sheila Mikhail, CEO & Co-Founder of AskBio, is an Alumna of Springboard’s New England 2004 innovation cohort and was a Northstar Honoree as part of Springboard’s 2019 Winners’ Circle Dinner. Sheila co-founded AskBio in 2001 with the unwavering belief that gene therapies could cure disease and change the world. AskBio’s therapeutic focus on neuromuscular, central nervous system, cardiovascular and metabolic diseases now has clinical trials underway for Pompe disease, Parkinson’s disease, and congestive heart failure. AskBio became a wholly-owned, independently operated, subsidiary of Bayer AG in late 2020 as a cornerstone of its newly formed Cell & Gene Therapy (CGT) platform. Sheila continues to set a high bar in gene therapy and Springboard is proud of her accomplishments and evolutionary changes in the healthcare industry. Sheila joined the Springboard Board of Directors in 2022.
